• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Precision Optics Corporation Inc.

    12/3/25 4:16:06 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email
    S-8 1 poci_s8.htm REGISTRATION STATEMENT

     

    As filed with the Securities and Exchange Commission on December 3, 2025

    Registration No. 333- 

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    PRECISION OPTICS CORPORATION, INC.
    (Exact name of registrant as specified in its charter)

     

    Massachusetts   04-2795294
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification Number)
         

    22 East Broadway

    Gardner, Massachusetts

      01440
    (Address of Principal Executive Offices)   (Zip Code)

     

    Precision Optics Corporation, Inc. 2022 Equity Incentive Plan

    Inducement Stock Option Award

    (Full title of the plans)

     

    Joseph N. Forkey

    Chief Executive Officer

    Precision Optics Corporation, Inc.

    22 East Broadway

    Gardner, Massachusetts 01440

    (978) 630-1800

    (Name, address, including zip code, and telephone number,

    including area code, of agent for service)

     

    Copies to:

     

    Thomas S. Brennan

    ArentFox Schiff LLP

    800 Boylston Street, 32nd Floor

    Boston, Massachusetts 02199

    (617) 973-6197

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934:

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

       

     

     

    EXPLANATORY NOTE

     

    This Registration Statement registers the offer and sale of 60,000 shares of common stock of Precision Optics Corporation, Inc. (the “Company”) for issuance under the Inducement Stock Award, and an additional 385,000 shares of common stock of the Company issuable under the Precision Optics Corporation, Inc. 2022 Equity Incentive Plan (the “Plan”) pursuant to its terms (2,758 of such shares may be issuable upon exercise of a non-qualified stock option award that has been granted under the Plan). In accordance with Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 (File Nos. 333-275180 and 333-285916), filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on October 26, 2023 and March 19, 2025, respectively, registering shares of its Common Stock, par value $0.01 per share, issuable under the Plan, are hereby incorporated by reference.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     2 

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with the rules and regulations of the Commission. The documents containing the information specified in Part I of Form S-8 will be delivered to the individual covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). 

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

     

    The following documents filed by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, filed with the Commission on September 29, 2025; the Amendment to the Registrant’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2025, filed with the Commission on October 28, 2025;
    (b) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Commission on November 13, 2025;
    (c) The Registrant’s Current Report on Form 8-K, filed with the Commission on October 3, 2025;
    (d) The description of the Registrant’s common stock contained in the registration statement on Form S-1, filed with the Commission on July 20, 2023, including any amendments or reports filed for the purpose of updating such descriptions.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein to be a part hereof from the date of filing of such documents (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with Commission rules).

     

    ITEM 4. DESCRIPTION OF SECURITIES.

     

    Not applicable.

     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.

     

    Not applicable.

     

     

     

     3 

     

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

     

    The Registrant is organized under the laws of the Commonwealth of Massachusetts. The Registrant’s officers and directors are indemnified as provided by the General Laws of Massachusetts, its Restated Articles of Organization, and its By-laws.

     

    Section 2.02(b)(4) of the Massachusetts Business Corporation Act, or the MBCA, provides that a corporation may, in its articles of organization, eliminate or limit a director’s personal liability to the corporation for monetary damages for breaches of fiduciary duty, except in circumstances involving (1) a breach of the director’s duty of loyalty to the corporation or its shareholders, (2) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) improper distributions, and (4) transactions from which the director derived an improper personal benefit.

     

    Section 8.51 of the MBCA permits the Registrant to indemnify a director if the individual (1) acted in good faith, (2) reasonably believed that his or her conduct was in the best interests of the corporation or at least not opposed to the best interests of the corporation, and (3) in the case of a criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. Section 8.51 also allows for indemnification of a director for conduct for which such individual is or would be exculpated under the charter provision referred to above. Section 8.52 of the MBCA requires that a corporation indemnify a director who was wholly successful, on the merits or otherwise, in the defense of any proceeding to which such director was a party because he was a director of the corporation.

     

    Section 8.56 of the MBCA permits a corporation to indemnify an officer (1) under those circumstances in which the corporation would be allowed to indemnify a director and (2) if such officer is not a director of the corporation, to such further extent as the corporation chooses provided that the liability does not arise out of acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law. Section 8.56 requires that a corporation indemnify an officer who was wholly successful on the merits or otherwise in the defense of any proceeding to which such officer was a party because he was a director of the corporation.

     

    Prior to the final disposition of a proceeding involving a director or officer, Sections 8.53 and 8.56 of the MBCA allow the Registrant to pay for or reimburse reasonable expenses. As a condition, the director or officer must deliver a written undertaking to repay the funds if the individual is determined not to have met the relevant standard of conduct, which determination is made in the same manner as the determination of whether an individual is entitled to indemnification. This undertaking may be accepted without security and without regard to the individual’s financial ability to make repayment. Another condition to advancement of expenses is that the individual submit a written affirmation of his or her good faith that he or she has met the standard of conduct necessary for indemnification (or that the matter involved conduct for which liability has been eliminated pursuant to the charter exculpation provision referred to above). Furthermore, Section 8.54 of the MBCA provides that a court may direct a corporation to indemnify a director or officer under certain circumstances.

     

    Section 8.58 of the MBCA allows a corporation to obligate itself in advance of the act or omission giving rise to a proceeding to provide indemnification to a director or officer or to advance funds or reimburse expenses. Such a commitment may be made in the corporation’s articles of organization or bylaws or in a resolution adopted or a contract approved by the board of directors or the shareholders.

     

    Under Section 8.51 of the MBCA, a director’s conduct with respect to an employee benefit plan for a purpose he reasonably believed to be in the interests of the participants in, and the beneficiaries of, the plan is conduct that satisfies the requirement that his conduct was at least not opposed to the best interests of the corporation. Unless ordered by a court as provided in the statute, we may not indemnify a director if his conduct did not satisfy the standards set forth above.

     

     

     

     4 

     

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.

     

    Not applicable.

     

    ITEM 8. EXHIBITS.

     

    Exhibit

    Number

      Description
    4.1   Restated Articles of Organization of Precision Optics Corporation, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K filed on September 28, 2023)
    4.2   Amended and Restated Bylaws of Precision Optics Corporation, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on July 11, 2014)
    4.3   Amendment to the Amended and Restated Bylaws of Precision Optics Corporation, Inc. effective May 13, 2022 (Incorporated by reference to Exhibit 3.5 to the Registrant’s Quarterly Report on Form 10-Q filed on May 16, 2022)
    4.4   Articles of Amendment to the Amended Articles of Organization as filed with the Commonwealth of Massachusetts on October 24, 2022; and Articles of Amendment as filed with the Commonwealth of Massachusetts on October 26, 2022, to override the earlier amendment (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on November 2, 2022)
    4.5   Articles of Amendment to the Amended Articles of Organization as filed with the Commonwealth of Massachusetts on October 27, 2022, to set revised effective date of reverse stock split (Incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on November 2, 2022)
    5*   Opinion of ArentFox Schiff LLP
    10.1*   Precision Optics Corporation, Inc. 2022 Equity Incentive Plan
    10.2   Stock Option Agreement made effective as of October 1, 2025 by and between Precision Optics Corporation, Inc. and Joseph Traut (Incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q filed on November 13, 2025)
    23.1*   Consent of ArentFox Schiff LLP (included in Exhibit 5)
    23.2*   Consent of Stowe & Degon LLC
    24   Power of Attorney (included on the signature page)
    107*   Filing fee table

    _____________________________

    * Filed herewith.

     

     

     

     

     5 

     

     

    ITEM 9. UNDERTAKINGS.

     

    A. The undersigned Registrant hereby undertakes:

     

    1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. 

     

     

     

     

     6 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the town of Gardner, Commonwealth of Massachusetts, on December 3, 2025.

     

      PRECISION OPTICS CORPORATION, INC.
      (Registrant)  
         
      By: /s/ Joseph N. Forkey  
        Joseph N. Forkey  
       

    Chief Executive Officer, President and Treasurer

    (Principal Executive Officer)

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Joseph N. Forkey or Wayne M. Coll as attorney-in-fact and agent, with full power of substitution and re-substitution, to sign on his or her behalf, individually and in any and all capacities, including the capacities stated below, any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated:

     

    SIGNATURE   TITLE   DATE
             
    /s/ Joseph N. Forkey   Chief Executive Officer, President and Director    
    Joseph N. Forkey   (Principal Executive Officer)   December 3, 2025
             
    /s/ Wayne M. Coll   Chief Financial Officer    
    Wayne M. Coll   (Principal Financial Officer and Principal Accounting Officer)   December 3, 2025
             
    /s/ Peter H. Woodward   Director, Chairman    
    Peter H. Woodward       December 3, 2025
             
    /s/ Buell G. Duncan   Director    
    Buell Duncan       December 3 2025
             
    /s/ Andrew J. Miclot   Director    
    Andrew J. Miclot       December 3, 2025
             
    /s/ Joseph J. Pellegrino, Jr.   Director    
    Joseph J. Pellegrino, Jr.       December 3, 2025
             

     

     

     

     7 

     

    Get the next $POCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    SEC Filings

    View All

    SEC Form S-8 filed by Precision Optics Corporation Inc.

    S-8 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    12/3/25 4:16:06 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Precision Optics Corporation Inc.

    SCHEDULE 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/21/25 5:30:20 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Precision Optics Corporation Inc.

    10-Q - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    11/13/25 4:15:47 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results

    GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025. Q1 2026 Financial Highlights (3 Months Ended September 30, 2025): Revenue was $6.7 million, a quarterly record, compared to $4.2 million in the same quarter of the previous fiscal year, representing growth of approximately 59%.Production revenue was $6.0 million, a quarterly record, compared to $2.6 million in the same quarter of the previous fis

    11/13/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Develop Custom High-End Borescope for Jet Engines

    GARDNER, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to design and build a next generation borescope system to be used to inspect the inside of jet engines from a large aerospace and defense company. The system involves the development of a high-end, small-diameter borescope designed in multiple configurations to measure critical components inside jet engines in the field. It will deliver greater-than-1080p HD resolution performance and is engineered to withstand the e

    11/11/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots

    GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to build sub-assemblies that will support an advanced augmented reality (AR) system for US Air Force fighter pilot training, powered by POC's next-generation optical sub-assembly design and manufacturing technologies. The program aims to allow pilots to wear AR headsets while in the air in their fighter jets, simulating combat training, without the need for secondary aircraft to be present. This reduces cost and the

    11/7/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Pellegrino Joseph P Jr

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 9:11:13 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Woodward Peter H

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:59 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Miclot Andrew J.

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:46 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025

    GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET. Call-in Information: Intere

    11/6/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

    GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

    5/8/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care